tions. Unlike other members of the class of nonnucleoside compounds, NSC 667952 remained active against virus isolates with the L1001 amino acid change in the RT. The compound was, however, highly sensitive to Y181C, K103N and K101E amino acid changes in the RT. The diarylsulphone selected for resistant virus populations which possessed the Y181C amino acid change in the reverse transcriptase and which exhibited enhanced sensitivity to the nonnucleoside inhibitors calanolide A and costatolide.
Summary
Structure-activity relationship evaluations with a series of diarylsulphone non-nucleoside reverse transcriptase (RT) inhibitors indicated that the steric properties of the molecule and compound Iipophilicity primarily contributed to the overall level of activity of the compounds against human immunodeficiency virus type 1 (HIV-1). The most active compounds in the diarylsulphone series had an orthonitro group and yielded anti-HIV activity at sub-micromolar concentrations. Compounds of the diarylsulphone class exhibited antiviral properties similar to other members of the pharmacologic class of HIV-1 specific nonnucleoside reverse transcriptase inhibitors, including activity in a wide variety of established and primary human cells, activity against a wide variety of laboratory and clinical virus isolates, and activity when challenged at high multiplicity of infection. Synergistic inhibition of HIV-1 was observed when the diarylsulphone NSC 667952 was used with the nucleoside analogues AZT, ddl, 3TC and d4T, the protease inhibitor KNI 272 and the sulphonated dye resobene; additive effects were observed when NSC 667952 was used with the nucleoside analogue ddC and other non-nucleoside RT inhibitors. The diarylsulphones exhibited a unique sensitivity profile when evaluated against both virus isolates and purified reverse transcriptase containing non-nucleoside reverse transcrlptase inhibitor resistance-engendering muta-
Introduction
The structurally diverse class of non-nucleoside reverse transcriptase inhibitors (NNRTls) includes compounds which are among the most potent anti-HIV agents identified (Merluzzi et al., 1990; Pauwels et al., 1990; Bader et al., 1991; Wu et al., 1991; Kashman et al., 1992; Klunder et aI., 1992; Maass et al., 1993; Buckheit et al., 1993 Buckheit et al., , 1994a Buckheit et al., , 1995b Richman et al., 1994; McMahon et al., 1995) . Each of these compounds inhibits human immunodeficiency virus type 1 (HIV-1) reverse transcriptase by reversible interaction with the enzyme at the NNRTI binding site in the palm domain of the p66 subunit of the RT (Cohen et al., 1991; Nunberg et al., 1991; Condra et al., 1992; Grob et el., 1992; Jacobo-Molina et al., 1993; Smerdon et al., 1994) . The compounds are relatively nontoxic to the host cell, suggesting they may be therapeutically useful, although high doses of the agents in clinical trials have been associated with an increased frequency of rashes and hepatic enzyme elevations (Balzarini et al., 1993a) . In addition, the NNRTls interact synergistically with AZT and other nucleoside RT inhibitors (Richman et al., 1991; Buckheit et aI., 1993 Buckheit et aI., , 1994b Buckheit et aI., , 1995a .
The therapeutic utility of these anti-HIV compounds, however, is severely compromised by the rapid appearance of drug-resistant virus isolates both in patients and in cell culture (Saag et al., 1993; Richman et al., 1994) . The highly specific interaction of the NNRTls at the hydrophobic binding site on the HIV-1 RT results in the ability of single amino acid changes in the NNRTI binding pocket to reduce or eliminate the inhibitory activity of the compound. A variety of drug-induced mutations have been described, including A98G, L1001, K103N, Vi 06A, V1081, E138K, T1391, Y181C, Y188C, G190A and P236L (Mellors et al., 1995) .
Recently, however, it has become increasingly apparent that the NNRTI class of compounds is quite diverse (Balzarini et al., 1993b,c; Dueweke et al., 1993) . This diversity may allow the identification of therapeutically beneficial combinations of compounds. It has been recently reported that distinct sub-classes of NNRTI-resistant virus isolates are defined by distinct mutations present in the RT, providing a means to select NNRTI combinations for use against HIV by cross-resistance evaluations (Buckheit et al., 1995a) . Potential NNRTI drug combinations are selected based on non-overlapping sensitivity phenotypes of compounds evaluated against drug-resistant virus isolates or RT with defined resistance-engendering mutations.
A variety of structurally distinct NNRTls have been identified through the efforts of the National Cancer Institute's high capacity anti-HIV drug screening programme (Bader et al., 1991; Kashman et al., 1992; Buckheit et al., 1993 Buckheit et al., , 1994a Buckheit et al., , 1995a McMahon et aI., 1995) . Synthetic efforts have continued in an effort to identify structural features of the NNRTls responsible for both anti-HIV activity and the rapid selection of highly resistant virus isolates. The diarylsulphone class of NNRTls exhibits potent anti-HIV activity in established and fresh human cells and synergisticallyinhibits HIV when used in combination with nucleoside analogues, sulphonated cell surface active agents and protease inhibitors. The diarylsulphones possess a unique sensitivity profile to drug-resistant virus isolates. These data indicate that the diarylsulphones may interact differently with the HIV-1 RT compared to other members of the NNRTI group and therefore may be useful inhibitors when used in combination with other anti-HIV agents, including NNRTls.
Results

Structure-activity relationships of the diarylsulphone series
The basic structure of the series of diarylsulphone compounds consists of two substituted phenyl groups linked by a sulphone (Table 1) . The synthesis and chemical characterization of the various analogues was performed as described (Gennaro and Zanger, 1972) according to the synthetic pathways described in Fig. 1 and Fig. 2 . As shown in Table 1 , the diarylsulphone analogues differ strikingly in their anti-HIV activities, depending on the position and/or substitution. The most active compounds in the series had an orthonitro group. When the nitro group was moved to the para-position, anti-HIV activity totally disappeared. Two compounds (compounds 1 and 12) without a nitro group had moderate to good anti-HIV activity. Several of the most active compounds (compounds 3, 10 and 17) had chloro groups on the ring containing the amine group. Compounds where a methyl group replaced a chloro (compounds 6, 9 and 16) were only slightly less active than the original compounds. The particular diarylsulphone selected for more extensive evaluation, NSC 667952, is presented as compound 10 in Table 1 . NSC 667952 exhibited a mean EC so concentration of 0.08 IlM and an IC so value of> 200 IlM.
The possible impact of compound lipophilicity on anti-HIV activity was also evaluated by calculating the theoretical partition coefficients (log P) of the compounds. All of the active compounds had calculated log P's between 2.39 and 3.56 with a log po of'" 3. When the log P dropped below 2.5 or exceeded 3.5, the compounds had no activity. The main exceptions to this generalization were the pnitro compounds (compounds 13 and 14) which had log P's of 2.86 and 3.01, respectively.
Range and mechanism of anti-HIV activity of NSC
667952
The diarylsulphone NSC 667952 was evaluated in a range of established and fresh human cells infected with a variety of laboratory and primary virus isolates ( Table 2) . The compound inhibited virus replication in T cells, B cells and monocyte-macrophages at concentrations ranging from 100 to 500 nM. In fresh human peripheral blood cells, the diarylsulphone inhibited HIV replication in a similar range of concentrations when using primary syncytium-inducing (SI) and non-syncytium-inducing (NSI) clinical virus isolates, as well as Iymphotropic and monocyte-macrophage-tropic virus isolates ( Table 2 ). The compound was determined to be inactive when evaluated against HIV-2 and SIV (Table 2) .
Additional range of action assays demonstrated that the NSC 667952, in contrast to results obtained with AZT, remained active when challenged at multiplicities of infection 1DO-fold greater than those employed in our standard assays (data not shown). The compound had to be present at the time of infection to exhibit anti-HIV activity. The diarylsulphone was inactive when evaluated for ability to inhibit virus production from chronically infected cells (Table 2 ).
In biochemical, mechanism based assays, the diarylsulphone was found to inhibit reverse transcriptase but was inactive in protease, integrase and gp120:CD4 interaction inhibitionassays at concentrations up to 100 IlM. The diarylsulphone was most active when evaluated using heteropolymeric ribosomal RNA (IC so = 0.1 IlM) or homopolymericpoly rC:oligo dG (IC so = 11 IlM) template:primer systems. As has been previously reported for other NNRTls (Buckheit et al., 1995a) ,the diarylsulphonewas relatively inactive when eval- Cells" NSC667952 Nevirapine AZT The diarylsulphone was evaluated in the XTI-based anti-HIV assay for activity in combination with a variety of known anti-HIV agents. These agents included the nucleoside RT inhibitors AZT, ddl, ddC, d4T and 3TC, the nonnucleoside RT inhibitors costatolide and UC10, the sulphonated virus attachment inhibitor resobene and the protease inhibitor KNI 272. The data obtained following performance of these combination antiviral assays with data analysis by MacSynergy " are summarized in Table 3 . Synergy volumes were calculated at the 95% confidence interval from the three dimensional product of the MacSynergy " program. These synergy volumes quantify the volume under the three dimensional surface. Highly synergistic inhibition of HIV was observed with the nucleoside analogues AZT and d4T when used in combination with NSC 667952 (synergy volumes greater than 150 IlM2%); synergistic inhibition of HIVwas observed with the nucleoside analogues ddl and 3TC, the attachment inhibitor resobene and the protease inhibitor KNI 272 when used in combination with the diarylsulphone (syn- 
Sensitivity of NSC 667952 to drug-resistant virus isolates
The diarylsulphone was evaluated against drug-resistant virus isolates selected in cell culture (Table 4) , as well as against virus isolates (Table 5 ) and purified RT (Table 6) obtained by site-directed mutagenesis. These studies were performed to evaluate the sensitivity of the compound against virus isolates possessing mutations yielding resistance to NNRTls. The diarylsulphone was determined to be inactive, even at high concentration, against virus isolates with the Y181 C mutation in the RT (Tables 4 and 5 ). The diarylsulphone was also determined to be inactive against virus isolates with amino acid changes conferring resistance to AZT together with the Y181 C change. Loss of sensitivity to NSC 667952 (5-to 15-fold) was observed with virus isolates possessing amino acid changes A98G, K101E, K103N, Vi 081 and Y188C in the RT. NSC 667952 was highly sensitive to amino acid changes Y181 C, Y188H, K103N and Vi 081. Antiviral activity was observed at control levels when the diarylsulphone was evaluated against virus isolates with the L74V (ddl-resistant), L1001, Vi 061, V179D, 4xAZT and 4xAZT + L1001 mutations in the RT. The activity of the diarylsulphone NSC 667952 was confirmed in biochemical RT inhibition assays when evaluated against purified RT possessing resistance-engendering mutations (Table 6 ) introduced by site-directed mutagenesis. Again, the diarylsulphones exhibited control levels of activity against RT with the L1001 amino acid change. Loss of activity of the compound was detected against RT with the mutations K103N and Y188L. Enhanced activity of the compound was detected against RT with the P236L amino acid change.
Selection and characterization of diarylsulphone-resistant virus isolates
Two virus isolates which were resistant to NSC667952 were rapidly selected in cell culture. Both of these virus isolates appeared within five passages in the presence of the compound and were determined to be insensitive to diarylsulphone at the highest concentration tested (61 J.!M). The final passage was performed in the presence of Maass et al., 1993; Richman et al., 1994; McMahon et al., 1995) , NSC 667952 was found to be active in a variety of established and fresh human cells infected with laboratory-derived and low passage clinical HIV-1 isolates, remained active when challenged at high Mal and interacted with AZT to synergistically inhibit HIV-1 (Buckheit et aI., 1995a,b) . In our hands, the activity of NSC 667952 against virus isolates with the NNRTI resistance-engendering L1001 amino acid change in the RT is unique. Testing of a wide variety of NNRTls in our laboratory has demonstrated that all are rendered less active by this mutation in the RT (Buckheit et al., 1995a,b) . The replacement of leucine by isoleucine at the opening of the NNRTI binding pocket presumably blocks the entry of nearly all of the large, inflexible NNRTls. Only the diarylsulphone described here, and a-APA, have thus far been found to have activity against viruses and RT with the bulky isoleucine at position 100. Efforts to rationally select combinations of NNRTls for use in patients through cross-resistance evaluations have focused on the identification of compounds which could be used to retard the development of resistance-engendering mutations or to select for mutations which would render the RT and the virus less fit for replication.
Our data indicate that the compound calanolide A (Kashman et al., 1992) , or its analogue costatolide, would effectively inhibit viruses with the Y181 C amino acid change in the RT but would remain sensitive to the amino acid changes L1001, K103N and Y188C (Buckheit et al., 1995a) . Use of calanolide A with the diarylsulphone NSC 667952 would inhibit the replication of viruses with the Y181C and L1001 amino acid changes. Further refinement of NNRTI combination therapy would require an additional compound which would inhibit the replication of viruses with amino acid changes in the RT which would permit continued virus replication in the presence of both compounds, such as K103N and Y188C. A third RT inhibitor, such as 3TC, may be useful in this combination 248 R. W. Buckheit Jret al. 
Discussion
Structure-activity relationships of a variety of diarylsulphone analogues determined that the most active compounds in the sulphone series had an essential orthonitro group. When the nitro group was moved to the para position, anti-HIV activity totally disappeared, suggesting that the effect of the nitro group owes more to its position (steric effect) than to its electronic effect. This conclusion is supported by previously published results which demonstrated that moving the orthonitro group to any other position led to a loss of anti-HIV activity . The structure-activity relationship evaluations also demonstrated the effect of compound lipophilicity on anti-HIV activity, indicating that further modifications to the diarylsulphone structure in order to improve on anti-HIV activity should result in log P as close to 3,0 as possible. The activity of the most potent diarylsulphone identified, NSC 667952 (Table 1 , compound 10), was extensively examined. Similar to the many described NNRTls (Merluzzi et al., 1990; Pauwels et al., 1990; Bader et aI., 1991; Wu et al., 1991; Kashman et al., 1992; Klunder et al., 1992; Buckheit et aI., 1993 Buckheit et aI., , 1994a Buckheit et aI., , 1995b ; (Wainberg et al., 1996) . The rapid appearance of drugresistant virus isolates indicates that the use of NNRTls in patients will require that complete cross-resistance evaluations, such as those reported here, be performed in order to determine all of the mutations that might yield resistance to the compound. In this way effective combinations of NNRTls with clinical potential might be defined.
Materials and Experimental Procedures: Chemistry
The structures of the compounds evaluated are shown in Table  1 . The purity of each of the compounds was established by their initial elemental analysis and NMR. From this analysis melting points were determined and all subsequent samples had the correct melting points, indicating chemical purity. GC/mass spectroscopy was also used to evaluate purity of the compounds. These analyses indicated that all of the compounds were greater than 99% pure. All of the tested compounds are secondary amines. Compounds 1-7 were derived from substituted tetrahydroquinolines (THO) and compounds 8-17 were prepared from substituted N-methyl anilines. Thirteen of the compounds have an orthonitro group on the sulphonic acid moiety. Two other compounds have paranitro groups, while two do not possess a nitro group. Additional substituents on the amine ring included CI, OH, CH 3 and CH 3 0 . On the sulphonic acid ring, the only additional substituent used was CI. All of the compounds were prepared via acid-catalyzed rearrangement of N-alkyl sulphonamides first described by Witt and Uermenyi (Witt and Uermenyi, 1913) . Additional work (Witt and Truttwin, 1914; Halberkahnn, 1921a Halberkahnn, .b, 1922 defined several of the parameters which favoured the rearrangement reaction. The sulphones derived from THO were first described by Gennaro and Zanger (1972) . The synthetic schemes are presented in Fig. 1 and Fig. 2 . If the N-alkylated ani-line was not commercially available, the unalkylated SUlphonamide was prepared according to Route A (Fig. 1 ). If available commercially, an N-methylaniline was converted to the SUlphonamide according to Route B (Fig. 1) . A similar scheme (Fig. 2 , Route C) was employed to prepare the THO sulphones.
Virology
Cells and viruses
The established human cells, laboratory derived virus isolates (including drug-resistant virus isolates) and low passage clinical virus isolates used in these evaluations have been previously described in detail (Buckheit et al., 1994a) . These cells were maintained in RPMI 1640 medium supplemented with 10% fetal bovine serum, 2 mM glutamine, penicillin (100 U mL-1 ) , and streptomycin (100~g mL-1 ) . Fresh human cells were obtained from the American Red Cross (Baltimore, MD, USA). Virus isolates with single amino acid changes in the reverse transcriptase were obtained from W. Schleif at Merck Research Laboratories (West Point, PA, USA) and have been described in detail (Byrnes et el., 1994) .
Materials
All experimental antiviral agents were obtained from the Developmental Therapeutics Program, Division of Cancer Treatment, National Cancer Institute. Crystalline stock materials were stored at -70°C and solubilized in 100% dimethylsulphoxide (DMSO). All stocks were diluted at least 400-fold prior to performing drug susceptibility assays. The reference anti-HIV compounds used in these studies and obtained from the NCI were 3'-azido-3'-deoxythymidine (AZT, NSC 602670) and nevi rapine (NSC 641530). The racemic 3TC obtained from the NCI was supplied by IAF BioChem. ELISA plates were obtained from Coulter Cytometry (Hialeah, FL, USA). Materials required for the performance of reverse transcriptase inhibition assays, anti-HIV assays, and for the growth and maintenance of established and fresh human cells have been previously described (Boyer et al., 1993; Buckheit et al., 1994a ).
Antiviral and cross-resistance assays
The HIV inhibitory activity of the compounds was evaluated in CEM-SS cells using a microtitre anti-HIV assay, which quantifies the ability of a compound to inhibit HIV-induced cell killing or HIV replication (Buckheit et al., 1994a) . Quantification was performed using the tetrazolium dye XTT, which is metabolized to a coloured, formazan product by viable cells. Antiviral and toxicity data are reported as the quantity of drug required to inhibit 50% of virus-induced cell killing or virus production (EC so) and the quantity of drug required to reduce cell viability by 50% (IC so).
Combination antiviral analysis
Analysis of drug combination assays was performed in CEM-SS cells acutely infected with the IIiB strain of HIV-1 as previously described (Buckheit et al., 1994b) utilizing the anti-HIV assay methodology described above. Statistical evaluations were performed according to the method of Prichard and Shipman (1990) . The results of the combination assays are presented three dimensionally at each combination concentration, yielding a surface of activity extending above (synergy) or below (antagonism) the plane of additivity. The volume of the surface is calculated and expressed as a synergy volume (IlM2%) calculated at the 95% confidence interval (Prichard and Shipman, 1990) . For these studies, synergy is defined as drug combinations yielding synergy volumes greater than 50 IlM2%. Slightly synergistic activity and highly synergistic activity have been defined as yielding synergy volumes of 50-100 IlM2% and > 100 IlM2%, respectively. Synergy volumes between 0 and 50 IlM2% are considered additive and synergy volumes less than 0 IlM2% are considered antagonistic.
RT inhibition assays
Analysis of the drug sensitivity of RT containing defined amino acid substitutions was performed as previously described (Boyer et al., 1993) .
Selection of drug resistant strains
Resistant virus isolates were selected in cell culture by serial passage of the IIIB strain of HIV-1 in CEM-SS cells in the presence of increasingconcentrationsof antiviralcompound.The initialselection was performed with a drug concentrationof twice the 50% effective concentration (EC so) of the compound as determined in the microtitre anti-HIV assay. With successive passages the drug concentration was increased two-fold to enhance the selective pressure on the virus. The final concentration used in the selection of the resistant virus isolate was 20 11M. Each passage of virus in the presence of compound was initiatedby infectionof the cells at an MOl of 0.01 and immediate addition of the diarylsulphoneto the culture. Neither the cells nor the virus were pretreated with compound prior to infection. Virus-containing, cell-free supematants were collected at the time of maximum virus production, titred and used to initiatethe next passage. Upon selection of a drug-resistant virus isolate, cross-resistance testing was performed according to the methods described for the performance of antiviral assays. Resistance has been defined in this study as a greater than fivefold increase in EC so concentration when compared to the activity of the compound against the wild type (IIIB) isolate.
Analysis of RT mutations
Direct sequencing of PCR amplified DNA, using dideoxynucleotide chain termination, was performed utilizing the Sequenase PCR Product Sequencing kit (USB-Amersham, Cleveland, OH, USA) per the manufacturer's protocol. Briefly, PCR amplified DNA was derived from the first 750 bp of the HIV-1 RT gene using the BLAA NE1 primer set; five additional sequencing primers were utilized to provide DNA sequences spanning the entire amplified RT region. Routinely, following completion of the DNA sequencing reactions, the dideoxynucleotide chain-terminated reaction products were resolved on a 6% acrylamide/bisacrylamide denaturing gel containing urea and glycerol tolerant buffer (USB-Amersham). Upon completion of electrophoresis, the DNA sequencing gels were dried (BioRad, CA, USA) and subjected to autoradiography using BioMax MR2 film (Kodak, Rochester, NY, USA). The resulting auto radiographs were digitized (Hitachi, CA, USA) and the reported DNA sequences were compiled and analysed utilizing the Wisconsin Sequence Analysis Package, Version 8.0 (Genetics Computer Group, Inc., Madison, WI, USA).
